DAX+0,57 % EUR/USD+0,32 % Gold0,00 % Öl (Brent)0,00 %

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

Nachrichtenquelle: PR Newswire (engl.)
02.03.2019, 15:29  |  763   |   |   

- 80 to 100% of BE ABLE 1 responders maintained a response of at least 90% disease improvement (PASI90) over 60 weeks with bimekizumab

- These positive results mark the longest-term data to date demonstrating durable PASI90/PASI100 outcomes to 60 weeks with investigational molecule bimekizumab, which potently and selectively neutralizes both IL-17A and IL-17F, two key pro-inflammatory cytokines

- UCB is validating these positive Phase 2b results with ongoing Phase 3 comparative studies of bimekizumab in psoriasis, and is studying it in other disease areas, including psoriatic arthritis and axial spondyloarthritis

BRUSSELS, March 2, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, presented positive data from the Phase 2b BE ABLE extension study of bimekizumab in patients with moderate-to-severe chronic plaque psoriasis, which showed nearly all BE ABLE 1 responders completing 60 weeks of bimekizumab treatment maintained complete or almost complete skin clearance. The results are the longest-term data so far investigating bimekizumab and further highlight the potential value of the molecule's unique dual mechanism of action, which potently and selectively neutralizes IL-17F in addition to IL-17A, two key cytokines driving inflammatory processes. Findings were presented at a late breaker session at the American Academy of Dermatology Annual Meeting (AAD) in Washington, DC.

"The long-term results observed in the BE ABLE 2 Phase 2b study suggest the meaningful difference that IL-17F inhibition, along with IL-17A inhibition, can make for psoriasis patients who need significant, long-term skin clearance," said Andrew Blauvelt, MD, MBA, an investigator in the trial and President of Oregon Medical Research Center in Portland, Oregon. "The results add to a growing body of evidence supporting the molecule's unique dual neutralization of both IL-17A and IL-17F cytokines across multiple inflammatory diseases, suggesting exciting potential."

"Despite recent advances in therapy, psoriasis patients still have profound unmet needs. Many patients do not experience long-term symptom resolution, and they often have limited confidence in long-term treatments. The positive results and rapid development of bimekizumab in psoriasis reflect UCB's dedication to connecting scientific innovation with greater patient value," said Emmanuel Caeymaex, Head of Immunology and Executive Vice President at UCB.

In the BE ABLE 1 study, up to 79% of patients achieved at least 90% skin clearance (PASI90) as soon as week 12, based on a dose range of 64mg, 160mg, 160mg with a 320mg loading dose, 320mg, or 480mg, administered every four weeks. Among these BE ABLE 1 responders, defined as achievement of PASI90 at week 12, 80-100% maintained the rigorous PASI90 measure for up to an additional 48 weeks based on a dose range of 160mg or 320mg, administered every 4 weeks, in the BE ABLE 2 extension study. Further, 70-83% and 78-100% of BE ABLE 1 responders maintained PASI100 and the Investigator's Global Assessment of response, respectively. The safety profile was consistent with previous studies, with no new safety findings observed. The most frequent treatment-emergent adverse events were oral candidiasis and nasopharyngitis. No cases of suicidal ideation/behavior, major adverse cardiac events, or inflammatory bowel disease were reported.

UCB also presented findings this week from the BE AGILE study of bimekizumab in ankylosing spondylitis and the BE ACTIVE study of bimekizumab in psoriatic arthritis. The safety and efficacy of bimekizumab have not been established, and it is not approved by any regulatory authority worldwide.

About Psoriasis
Psoriasis is a chronic, immune-mediated inflammatory disease associated with prominent skin manifestations that affects approximately 1–3% of the population, or about 125 million people worldwide, although rates appear to vary by ethnicity, and estimates are sensitive to determination method.i Psoriatic arthritis occurs in up to 41% of patients with psoriasis,ii and is typically characterized by inflammation, pain and swollen joints.iii

Unmet needs remain in the treatment of psoriasis. A population-based survey identified that approximately 30% of psoriasis patients reported that their primary goals of therapy, including keeping symptoms at bay, reducing itching, and decreasing flaking were not met with their current treatment. iv Failure to achieve or retain complete and lasting disease resolution across the multiple manifestations of psoriatic disease, including joints and other musculoskeletal symptoms, negatively impacts risk of comorbidities, disease progression and quality of life, which is most likely multifactorial.v, vi, vii,viii

About Bimekizumab
Bimekizumab is an investigational novel humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17A and IL-17F have similar pro-inflammatory functions and independently cooperate with other inflammatory mediators to drive chronic inflammation and damage across multiple tissues. 

Seite 1 von 6

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors